Marcos de Lima

1997–2025 年に発表

141
論文数
19,118
被引用数
85
h 指数
135
i10 指数

被引用数

Marcos de Lima の年別被引用数1997 年: 被引用 1 件1998 年: 被引用 3 件1999 年: 被引用 8 件2000 年: 被引用 4 件2001 年: 被引用 4 件2002 年: 被引用 4 件2003 年: 被引用 30 件2004 年: 被引用 24 件2005 年: 被引用 59 件2006 年: 被引用 71 件2007 年: 被引用 89 件2008 年: 被引用 93 件2009 年: 被引用 119 件2010 年: 被引用 140 件2011 年: 被引用 116 件2012 年: 被引用 118 件2013 年: 被引用 131 件2014 年: 被引用 128 件2015 年: 被引用 146 件2016 年: 被引用 114 件2017 年: 被引用 116 件2018 年: 被引用 99 件2019 年: 被引用 535 件2020 年: 被引用 565 件2021 年: 被引用 524 件2022 年: 被引用 504 件2023 年: 被引用 317 件2024 年: 被引用 588 件2025 年: 被引用 214 件2026 年: 被引用 3 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,947 件、この内訳の 27.9%中国: 引用元論文 546 件、この内訳の 7.8%ドイツ: 引用元論文 496 件、この内訳の 7.1%イタリア: 引用元論文 425 件、この内訳の 6.1%イギリス: 引用元論文 390 件、この内訳の 5.6%フランス: 引用元論文 382 件、この内訳の 5.5%スペイン: 引用元論文 281 件、この内訳の 4%オランダ: 引用元論文 229 件、この内訳の 3.3%カナダ: 引用元論文 205 件、この内訳の 2.9%日本: 引用元論文 168 件、この内訳の 2.4%イスラエル: 引用元論文 167 件、この内訳の 2.4%スイス: 引用元論文 145 件、この内訳の 2.1%
0%27.9%その他 22.9%

分野

  • Medicine82.2%
  • Biochemistry, Genetics and Molecular Biology8.3%
  • Immunology and Microbiology7.8%
  • Engineering0.3%
  • Materials Science0.2%
  • Computer Science0.2%
  • その他1%

トピック

  • Hematopoietic Stem Cell Transplantation14.1%
  • Acute Myeloid Leukemia Research10.3%
  • CAR-T cell therapy research5.8%
  • Acute Lymphoblastic Leukemia research5.6%
  • Immune Cell Function and Interaction5.4%
  • T-cell and B-cell Immunology3%
  • その他55.8%

共著者

全論文

検索で開く
  1. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , - Frontiers in Immunology 2021 被引用: 114

  2. Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma

    著者: , , , , , , , , , , - Cancer Discovery 2022 被引用: 88

  3. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba, Martin S. Tallman - Journal of the National Comprehensive Cancer Network 2021 被引用: 326

  4. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew J. Wieduwilt, Kristina M. Gregory, OCN, Lydia J. Hammond, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2019 被引用: 424

  5. Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

    著者: , , , , , , , - Biology of Blood and Marrow Transplantation 2014 被引用: 354

  6. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients

    著者: , , , , , , , , , , , - Blood Advances 2020 被引用: 211

  7. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eunice S. Wang, Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2017 被引用: 655

  8. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 435

  9. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 74

  10. Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Frontiers in Immunology 2020 被引用: 97

  11. Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression

    著者: , , , , , , , , , , , , , , , , , , , , , - Leukemia 2021 被引用: 92

  12. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models

    著者: , , , , , , - PLoS ONE 2018 被引用: 144

  13. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2020 被引用: 112

  14. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

    著者: , , , , , , , , , , , - Scientific Reports 2019 被引用: 129

  15. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nasheed Hossain, Christopher G. Kanakry, Mohamed A. Kharfan‐Dabaja, Nandita Khera, Yener Koç, Hillard M. Lazarus, Jong Wook Lee, Johan Maertens, Rodrigo Martino, Joseph P. McGuirk, Reinhold Munker, Hemant S. Murthy, Ryotaro Nakamura, Sunita Nathan, Taiga Nishihori, Neil Palmisiano, Sagar S. Patel, Joseph Pidala, Rebecca L. Olin, Richard F. Olsson, Betül Oran, Olle Ringdén, David A. Rizzieri, Jacob M. Rowe, Mary Lynn Savoie, Kirk R. Schultz, Sachiko Seo, Brian C. Shaffer, Anurag K. Singh, Melhem Solh, Keith Stockerl‐Goldstein, Leo F. Verdonck, John L. Wagner, Edmund K. Waller, Marcos de Lima, Brenda M. Sandmaier, Mark R. Litzow, Dan Weisdorf, Rizwan Romee, Wael Saber - Blood Advances 2019 被引用: 128

  16. Steroid-Refractory Acute GVHD: Predictors and Outcomes

    著者: , , , , , , , , , , , , - Advances in Hematology 2011 被引用: 236

  17. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes

    著者: , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2018 被引用: 148

  18. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

    著者: , , , , , , , , , , , - American Journal of Hematology 2018 被引用: 133

  19. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

    著者: , , , , , , , , , - Bone Marrow Transplantation 2018 被引用: 131

  20. In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells

    著者: , , , , , , , , , , , , , , , , , , , , , , - JCI Insight 2022 被引用: 47

  21. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy

    著者: , , , , , - Radiology 2021 被引用: 32

  22. High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation

    著者: , , , , , , , , , - Transplantation 2009 被引用: 282

  23. Repression of GSK3 restores NK cell cytotoxicity in AML patients

    著者: , , , , , , , , , - Nature Communications 2016 被引用: 112

  24. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aric C. Hall, Meagan A. Jacoby, Jeffrey E. Lancet, Gabriel N. Mannis, Anthony S. Stein, Alice S. Mims, David A. Rizzieri, Rebecca L. Olin, Alexander E. Perl, Gary J. Schiller, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Mónica L. Guzmán, Gail J. Roboz, Joseph D. Khoury, Muzaffar H. Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan F. Madanat, Mohamed A. Kharfan‐Dabaja, Anna Pawłowska, Justin Taylor, Martin S. Tallman, Prajwal Dhakal, Andrew A. Lane - Blood 2022 被引用: 56